Author

Hallam M. Gugelmann

Observed names: Gugelmann, Hallam, H Gugelmann, H. Gugelmann, Hallam Gugelmann

Observed institutions: University of North Carolina at Chapel Hill, San Francisco VA Medical Center, University of California, San Francisco, Genentech, Hospital of the University of Pennsylvania, California Pacific Medical Center, VA San Diego Healthcare System, University of Pennsylvania

ORCID: 0000-0001-6344-7203

Observed ORCID: 0000-0001-6344-7203

OpenAlex ID: A5091241406

Differential Prescribing of Opioid Analgesics According to Physician Specialty for Medicaid Patients with Chronic Noncancer Pain Diagnoses

2014 · Chris Ringwalt, Hallam Gugelmann, et al. · Pain Research and Management · 159

PDF

Can Prescription Drug Monitoring Programs Help Limit Opioid Abuse?

2011 · Hallam M. Gugelmann, Jeanmarie Perrone · JAMA · 108

Racial Disparities Across Provider Specialties in Opioid Prescriptions Dispensed to Medicaid Beneficiaries with Chronic Noncancer Pain

2014 · Chris Ringwalt, Andrew W. Roberts, et al. · Pain Medicine · 68

PDF

‘Crazy Monkey’ Poisons Man and Dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid

2014 · H. Gugelmann, R. Gerona, et al. · Clinical Toxicology · 61

Windmills and Pill Mills: Can PDMPs Tilt the Prescription Drug Epidemic?

2012 · Hallam Gugelmann, Jeanmarie Perrone, et al. · Journal of Medical Toxicology · 45

PDF

Multidisciplinary intervention decreases the use of opioid medication discharge packs from 2 urban EDs

2013 · Hallam Gugelmann, Frances S. Shofer, et al. · The American Journal of Emergency Medicine · 38

Snakebites and climate change in California, 1997–2017

2018 · Caleb Phillips, Grant S. Lipman, et al. · Clinical Toxicology · 26

Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation

2022 · Hubert Chen, Rebecca Kunder, et al. · Pulmonary Pharmacology & Therapeutics · 14

Butanediol Conversion to Gamma‐Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole

2018 · Evangelia Liakoni, Hallam Gugelmann, et al. · Clinical Pharmacology & Therapeutics · 12

PDF

Young Woman With Seizures

2015 · Kai Li, Hallam Gugelmann, et al. · Annals of Emergency Medicine · 5

Beau's Lines After Cardiac Arrest

2013 · Hallam M. Gugelmann, David F. Gaieski · Therapeutic Hypothermia and Temperature Management · 5

OS-059 Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2b trial (VANTAGE): 28-week interim results

2025 · Michael Heneghan, Mitchell Shiffman, et al. · Journal of Hepatology · 4

Surface internet marketplace presence and availability of NPS sold as research chemicals: a snapshot study

2019 · Stephen L. Thornton, Michael A. Darracq, et al. · Toxicology Communications · 4

The Prescription Opioid Epidemic: Repercussions on Pediatric Emergency Medicine

2012 · Hallam M. Gugelmann, Lewis S. Nelson · Clinical Pediatric Emergency Medicine · 4

Cardiac Conduction and Rate Disturbances

2016 · Hallam Gugelmann, Neal Benowitz · Springer eBooks · 3

LBO-006 Efficacy and safety of volixibat, an IBAT inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: results of the VISTAS trial

2026 · Cynthia Levy, Gideon M. Hirschfield, et al. · Journal of Hepatology · 1

Cardiac Conduction and Rate Disturbances

2017 · Hallam Gugelmann, Neal Benowitz · Springer eBooks · 1

Acute human toxicity after the ingestion of cabezon,scorpaenichthys marmoratus, roe

2014 · Charles W. O'Connell, Rick Clark, et al. · Clinical Toxicology · 1

PDF

Prescription Drug Monitoring Programs—Reply

2012 · Hallam M. Gugelmann · JAMA · 1

O6 Efficacy and safety of volixibat, an IBAT Inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: Results of the VISTAS trial

2026 · Deepak Joshi, Gideon M Hirschfield, et al.

PDF

Exploring the role of ileal bile acid transporter inhibitors, like volixibat, in the regulation of IL-31 and serum bile acids in patients with primary biliary cholangitis: Preliminary results from the VANTAGE trial

2026 · J Trebicka, A Bonder, et al. · Zeitschrift für Gastroenterologie

Volixibat leads to improvements in fatigue and sleep for adults with primary biliary cholangitis: Data from VANTAGE

2026 · J Trebicka, K V Kowdley, et al. · Zeitschrift für Gastroenterologie

Tu2024 VOLIXIBAT LEADS TO IMPROVEMENTS IN FATIGUE AND SLEEP FOR ADULTS WITH PRIMARY BILIARY CHOLANGITIS: DATA FROM VANTAGE

2026 · Mitchell L. Shiffman, Debra Weinstein, et al. · Gastroenterology

Tu2023 EXPLORING THE ROLE OF VOLIXIBAT, AN ILEAL BILE ACID TRANSPORTER INHIBITOR, IN THE REGULATION OF IL-31 AND SERUM BILE ACIDS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: PRELIMINARY RESULTS FROM THE VANTAGE TRIAL

2026 · Mitchell L. Shiffman, Alan Bonder, et al. · Gastrointestinal Endoscopy

2026 · Mitchell L. Shiffman, Alan Bonder, et al. · Gastroenterology

Works count: 35

Citation count: 560

H-index: 9

I10-index: 9